Evidence map›Paper›PMID 35290991›Full record

ArticlePloS one2022

Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery.

Daniela Fux, Moritz Metzner, Johanna Brandl, Melanie Feist, Magdalena Behrendt-Wippermann, Anne von Thaden, Christine Baumgartner

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Daniela FuxInstitute of Pharmacology and Toxicology, Clinical Pharmacology, University of Veterinary Medicine, Vienna, Austria.
Moritz MetznerClinic for Ruminants with Ambulatory and Herd Health Services, Center for Clinical Veterinary Medicine, Ludwig-Maximilians-University of Munich, Oberschleißheim, Bavaria, Germany.ORCID 0000-0003-0752-6059
Johanna BrandlCenter of Preclinical Research, Klinikum rechts der Isar, Technical University of Munich, Bavaria, Germany.
Melanie FeistClinic for Ruminants with Ambulatory and Herd Health Services, Center for Clinical Veterinary Medicine, Ludwig-Maximilians-University of Munich, Oberschleißheim, Bavaria, Germany.
Magdalena Behrendt-WippermannClinic for Ruminants with Ambulatory and Herd Health Services, Center for Clinical Veterinary Medicine, Ludwig-Maximilians-University of Munich, Oberschleißheim, Bavaria, Germany.
Anne von ThadenGerman Center for Neurodegenerative Diseases (DZNE), Munich, Bavaria, Germany.
Christine BaumgartnerCenter of Preclinical Research, Klinikum rechts der Isar, Technical University of Munich, Bavaria, Germany.ORCID 0000-0001-6133-5099
Institute of Bioinformatics and Systems Biology · DETUM Klinikum · DEGerman Center for Neurodegenerative Diseases · DEUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This preliminary clinical investigation of the pharmacokinetic behavior of the main metamizole (dipyrone) metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in calves undergoing umbilical surgery is part of an already published main study. A single intravenous dose of metamizole was added to ketamine/xylazine/isoflurane anesthesia. Eight Simmental calves weighing 90 ± 10.8 kg and aged 47.6 ± 10.4 days received 40 mg/kg metamizole intravenously 10 minutes prior to general anesthesia. Blood samples were collected over 24 hours and analyzed for 4-MAA and 4-AA. Meloxicam was additionally given twice: 2.5 hours pre- and 20.5 hours postsurgically. The pharmacokinetic profile of 4-MAA was best fitted to a two-compartment model and was characterized by a fast distribution half-life and slow elimination half-life (t½alpha = 5.29 minutes, t½beta = 9.49 hours). The maximum concentration (Cmax 101.63 μg/mL) was detected at the first measurement time point 15 minutes after administration. In contrast, 4-AA showed fast, high and biphasic plasma peak concentration behavior in five calves (2.54-2.66 μg/mL after 15-30 minutes, and 2.10-2.14 μg/mL after 2-3.5 hours) with a t½beta of 8.87 hours, indicating a rapid distribution and subsequent redistribution from well-perfused organs. Alternatively, three calves exhibited a slower and lower monophasic plasma peak concentration (1.66 μg/mL after 6.5 hours) with a t½beta of 6.23 hours, indicating slow accumulation in the intravascular compartment. The maximum concentration and area under the plasma concentration curve (AUC) of 4-AA were lower than those of 4-MAA. This metabolic behavior supports our already published data on clinical monitoring and plasma cortisol concentrations (PCCs). Compared to those of saline controls, lower PCCs correspond to the t½alpha of 4-MAA. Data on Tmax and t½beta also match these clinical observations. However, further studies are required to assess the exact analgesic mechanism and potency of the metamizole metabolites in calves.

Indexed as

DipyroneKetamineAmpyroneAnalgesicsAnimalsCattleXylazineAmpyroneAnalgesicsDipyroneKetamineXylazine

Identifiers

PMID35290991
PMCPMC8923478
OpenAlexW4221003035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.